J
John R. Lake
Researcher at University of Minnesota
Publications - 267
Citations - 22434
John R. Lake is an academic researcher from University of Minnesota. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 75, co-authored 257 publications receiving 20846 citations. Previous affiliations of John R. Lake include University of Virginia & Baylor University Medical Center.
Papers
More filters
Journal ArticleDOI
Model for end-stage liver disease (MELD) and allocation of donor livers
Russell H. Wiesner,Erick B. Edwards,Richard B. Freeman,Ann M. Harper,Ray Kim,Patrick S. Kamath,Walter K. Kremers,John R. Lake,Todd K. Howard,Robert M. Merion,Robert A. Wolfe,Ruud A.F. Krom,Paul M. Colombani,Paige C. Cottingham,Stephen P. Dunn,John J. Fung,Douglas W. Hanto,Sue V. McDiarmid,John M. Rabkin,Lewis W. Teperman,Jeremiah G. Turcotte,Lynn Rothberg Wegman +21 more
TL;DR: Data suggest that the MELD score is able to accurately predict 3-month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers.
Journal ArticleDOI
The new liver allocation system: Moving toward evidence‐based transplantation policy
Richard B. Freeman,Russell H. Wiesner,Ann M. Harper,Sue V. McDiarmid,John R. Lake,Erick B. Edwards,Robert M. Merion,Robert Wolfe,Jeremiah G. Turcotte,Lewis W. Teperman +9 more
TL;DR: The development and initial implementation of a continuous disease severity scale that uses objective, readily available variables to predict mortality risk in patients with end‐stage liver disease and reduce the emphasis on waiting time is described.
Journal ArticleDOI
Predictors of patient and graft survival following liver transplantation for hepatitis C
Michael Charlton,Eric C. Seaberg,Russell H. Wiesner,James E. Everhart,Rowen K. Zetterman,John R. Lake,Katherine M. Detre,Jay H. Hoofnagle +7 more
TL;DR: While long‐term patient and graft survival following liver transplantation for end‐stage liver disease secondary to HCV are generally comparable with that of most other indications, higher pretransplantationHCV‐RNA titers are strongly associated with poor survival among HCV‐infected recipients.
Journal ArticleDOI
Recurrent and acquired hepatitis C viral infection in liver transplant recipients.
Teresa L. Wright,Teresa L. Wright,Teresa L. Wright,Elizabeth Donegan,Elizabeth Donegan,Elizabeth Donegan,Henry H. Hsu,Henry H. Hsu,Henry H. Hsu,Linda D. Ferrell,Linda D. Ferrell,Linda D. Ferrell,John R. Lake,John R. Lake,John R. Lake,Michael Kim,Michael Kim,Michael Kim,Connie Combs,Connie Combs,Connie Combs,Sean Fennessy,Sean Fennessy,Sean Fennessy,John P. Roberts,John P. Roberts,John P. Roberts,Nancy L. Ascher,Nancy L. Ascher,Nancy L. Ascher,Harry B. Greenberg,Harry B. Greenberg,Harry B. Greenberg +32 more
TL;DR: Although HCV infection recurs posttransplant in almost all infected patients, acquisition of theHCV infection with transplant is common, and although many patients with postTransplant viremia have little evidence of histologic hepatitis, significant hepatic damage may occur.
Journal ArticleDOI
Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome
Russell H. Wiesner,A. Jake Demetris,Steven H. Belle,Eric C. Seaberg,John R. Lake,Rowen K. Zetterman,James E. Everhart,Katherine M. Detre +7 more
TL;DR: The histological severity of rejection was an important prognosticator: the use of antilymphocyte preparations was higher, and the time to death or retransplantation was shorter, for patients with severe rejection, calling into question whether complete elimination of all rejection or alloreactivity is a desirable goal in liver transplantation.